Roman Michael F, Chairman and CEO, has filed 46 Form 4 transactions across three companies, but the pattern is overwhelmingly one-directional: he has not made a single open-market purchase, while selling roughly $14.2 million in stock. The selling is concentrated in 3M (MMM), where on January 29, 2025, he executed 16 separate open-market sales totaling approximately $1.6 million. Individual sale values ranged from a modest $761.61 to a substantial $303,746.02, with several mid-sized transactions between $40,000 and $290,000. This cluster of sales on a single date suggests a systematic disposition rather than sporadic activity, though the filings do not indicate whether these were pre-arranged trades.
His recent activity, however, has shifted away from selling entirely. Over the past year, Roman has reported only compensation-related grants (code "A") in Abbott Laboratories (ABT) and Waystar Holding Corp. (WAY), with no sales since the January 2025 MMM block. The ABT grants are quarterly and modest—ranging from $36,858.71 to $37,747.84—and appear to be routine equity awards rather than discretionary transactions. A February 2025 MMM filing also shows a grant (code "A") paired with a tax-withholding event (code "F") valued at zero, which is a standard mechanical adjustment.
The overall picture is a classic insider profile: heavy selling in a legacy position (MMM), followed by a quiet period of only automatic compensation awards. The $187,635.87 in total acquired value stems entirely from these grants, not purchases, reinforcing that Roman has no recent conviction-buying signal. His bias is clearly toward liquidity, with the January 2025 MMM sales representing the bulk of his disclosed activity, while his current holdings in ABT and WAY are being accumulated only through scheduled equity compensation.
AI-assisted summary